Kornimate/medical-research-clean huggingface dataset:
effects of high-resistance inspiratory muscle strength training on cardiorenal and vascular function in youth and young adults with type 2 diabetes

Conditions: Diabetes Mellitus Type 2

Summary: high-resistance, short-duration inspiratory muscle strength training (imst) is a novel lifestyle intervention involving 30 inhalations against a resistive load which requires only \~5 min/day and is thus ideal for youth with t2d (y-t2d). investigators seek to 1: assess changes in casual and 24-hr sbp, endothelial function, and arterial stiffness after 3 months of imst vs. sham training in y-t2d, 2: define changes in egfr andalbuminuria after 3 months of imst vs. sham in y-t2d, 3: interrogate mechanisms of imst by translational assessments of no bioavailability, endothelial no synthase (enos) activation, and ros/oxidative stress, and determine the role of circulating factors.


Eligibility criteria:
inclusion criteria: aged 14-40, have had t2d for a least one year, hba1c less than 12%. - exclusion criteria: have had type ii diabetes for more than 18 years, estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73m2 or albumin-to-creatinine ratio (acr) greater than 2200mg/g, blood pressure greater than 160/100 mm hg. -

Keywords: type 2 diabetes inspiratory strength training blood pressure kidney health cardiovascular function diabetic kidney disease
safety and efficacy of pegylated exenatine injection (pb-119) in drug-naïve t2dm subjects

Conditions: Type 2 Diabetes Mellitus (T2DM)

Summary: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of pb-119 in drug-naïve t2dm subjects.

the study included a maximum 2-week screening period, a 4-week single-blind introduction period, a 24-week double-blind treatment period, a 28-week open extension treatment period, and a 4-week safety follow-up period. at the end of the single-blind entry period, eligible subjects were randomly assigned to two different administration groups in a 1:1 ratio and received a 24-week double-blind treatment. all subjects who completed the double-blind treatment entered the open extension treatment phase.open extension treatment with subcutaneous injection of 150μg pb-119 once a week for 28 weeks. safety follow-up was conducted 4 weeks after the end of treatment/completion of early exit visit in the open extension period.

Eligibility criteria:
inclusion criteria: * male or female, aged 18\~75 years old; * confirmed t2dm patients meet the diagnostic criteria for type 2 diabetes published by who1999； * 18.5 kg/m2 \< bmi \< 40.0 kg/m2 at screening; * 7.5% ≤ hba1c ≤ 11.0% at screening; * 7.0% ≤ hba1c ≤ 10.5% when the random; * 18.5 kg/m2 \< bmi \< 40.0 kg/m2 during screening and before randomization exclusion criteria: * t1dm; * continuous use of insulin for more than 14 days within 1 year before screening or before randomization； * treatment with any dipeptidylpeptidase 4 (dpp-4) inhibitor or glucose-dependent insulin-stimulating peptide (gip) or/and glucagon-like peptide-1 (glp-1) receptor agonist prior to screening or randomized prior treatment； * screening for any of the following heart diseases within the first 6 months or before randomization； * patients whose hypertension was not effectively controlled during screening or before randomization (after resting ≥5 minutes, systolic blood pressure ≥160mmhg and/or diastolic blood pressure ≥100mmhg)； * serum amylase or lipase \>3×uln or those with previous diagnosis of acute/chronic pancreatitis were screened or randomly screened； * screening for severe trauma or infection that may affect glycemic control within the first month or before randomization； * a history or family history of medullary thyroid carcinoma (mtc) or multiple endocrine adenomatosis type 2 (men2)； * known to be allergic or intolerant to the study drug or metformin； * female subjects during pregnancy or lactation.
effects of rosiglitazone on serum ghrelin and peptide yy levels

Conditions: Type 2 Diabetes Mellitus; Obesity

Summary: we aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.


Eligibility criteria:
inclusion criteria: * newly diagnosed, drug naive women with type 2 diabetes exclusion criteria: * presence of severe cardiovascular disease (eg, new york heart association class iii or iv congestive heart failure or a history of myocardial infarction or stroke) * presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders
phase i/ib study of gwn323 alone and in combination with pdr001 in patients with advanced malignancies and lymphomas

Conditions: Solid Tumors; Lymphomas

Summary: the purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. this is a multi-center, open-label phase i/ib study. the study consists of two dose escalation parts and two dose expansion parts testing gwn323 as a single agent or gwn323 in combination with pdr001. the dose escalation parts will estimate the mtd and/or rde and test different dosing schedules. the dose expansion parts of the study will use the mtd/rde determined in the dose escalation part to assess the activity, safety and tolerability of the investigational products in patients with specific types of cancer and lymphomas. approximately 264 adult patients with advanced solid tumors or lymphomas will be enrolled.


Eligibility criteria:
inclusion criteria: * patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery. * histologically documented advanced or metastatic solid tumors or lymphomas * must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. patient must be willing to undergo a new tumor biopsy at screening * ecog performance status ≤ 2. exclusion criteria: * presence of symptomatic central nervous system (cns) metastases, or cns metastases that require local cns-directed therapy (such as radiotherapy or surgery). * patients diagnosed with t-cell lymphomas. * patients with prior allogenic transplants. * patients previously treated with anti-gitr therapy. * history of severe hypersensitivity reactions to other mabs. * patients intolerant to prior immunotherapy (unable to continue/receive due to immune-related ae). other protocol-defined inclusion/exclusion criteria may apply.

Keywords: advanced solid tumors lymphomas gwn323 pdr001 advanced malignancies anti-gitr anti-pd-1 adults
ioflupane i123 (datscan) and positron emission tomography-computed tomography fludeoxyglucose (pet-ct fdg) to assess brain function of parkinson patients' first degree relatives

Conditions: Parkinson Disease

Summary: parkinson disease is one of the most common neurodegenerative illnesses. first degree relatives of parkinson patient are in high risk for developing the disease. we will try to detect early changes in brain metabolism before the appearance of parkinson symptoms. participants: first degree relatives of diagnosed parkinson patients that carry a gene mutation in either lrrk2 or gba genes. the examination results will be given to the participants by a doctor from the neurology department.


Eligibility criteria:
inclusion criteria: * healthy first degree relatives of diagnosed parkinson patients exclusion criteria: * patients unable to understand and sign an informed consent * minors * people with psychiatric disorders or a history of major head trauma

Keywords: parkinson fdg pet-ct i123 dat scan first degree relatives of diagnosed parkinson patients with no clinical evidence of movement disorders
acute effects of walking exercise on brain functioning in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the project will involve a within-subjects, repeated-measures research design. participants will initially be screened for relevant inclusion/exclusion criteria for maximizing safety of participating in an exercise study. if a participant meets those inclusion/exclusion criteria, they will visit kessler foundation three times. the first visit will involve a baseline session where participants will complete several cognitive tests. this will be followed by a training session, where participants will be provided with a fitbit, and will be trained by research staff to walk at a rate of 100 steps per minute. once participants demonstrate proficiency at walking at this rate using the fitbit, participants will complete several questionnaires, followed by a maximal, graded exercise test to determine cardiorespiratory fitness. one week later, participants will return to kessler foundation to complete 1 of 2 experimental sessions that will be delivered in a random order that further will be counterbalanced across participants (to minimize the potential effects of session order on brain function and blood flow, respectively). both experimental sessions will follow the same structure. first, participants will undertake a 30-minute mri scan at kessler foundation to measure brain function and brain blood flow. immediately following the mri scan, participants will engage in either 20 minutes of treadmill walking exercise or 20 minutes of overground walking exercise at a rate of 100 steps per minute. immediately following the 20-minute exercise bouts, participants will undertake another mri scan for measuring brain function and brain blood flow. participants will return to kessler foundation a third time to complete the opposite experimental session that was not completed during the second visit (i.e., overground walking exercise if treadmill walking exercise was completed during the second visit). in total, each participant will undergo four mri scans over the course of the study (i.e., pre-treadmill, post-treadmill, pre-overground, post-overground). .


Eligibility criteria:
inclusion criteria: * clinically-definite ms diagnosis * relapse-free for at least 30 days * low risk for contraindications for exercise testing * low risk for contraindications for mri * historically physically inactive prior to ms diagnosis * historically highly physically active prior to ms diagnosis exclusion criteria: * diagnosis of uncontrolled major depressive disorder, schizophrenia, bipolar disorder i or ii, or substance use disorders * taking medications that can affect cognition (e.g., antipsychotics, benzodiazepines) * historically moderately physically active prior to ms diagnosis

Keywords: exercise mri walking
treatment of pulmonary hypertension group ii study

Conditions: Pulmonary Hypertension (PH) Due to Left Heart Disease

Summary: the objective of this study is to assess the safety and initial effectiveness of the tivus™ system when used for pulmonary artery denervation in group ii ph patients through change in clinical parameters including hemodynamics, exercise tolerance, and quality of life. this is a prospective, multi-center, non-randomized, open-label clinical trail. the study will be conducted in up to 3 centers and will recruit up to 15 patients diagnosed with pulmonary hypertension due to left heart disease that demonstrate combined pre and post capillary involvement with pvr\>3 wood units.


Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study obtained from the patient, according to local regulations, prior to initiation of any study mandated procedure. * male or female, ≥ 18 years of age at the time of screening * patient with known pulmonary hypertension (ph) due to left heart disease (who group ii) diagnosed as either hfpef or hfref at chronic state receiving stable guideline directed medical therapy. * combined post-capillary and precapillary pulmonary hypertension diagnosis confirmed by hemodynamic evaluation performed prior to screening or during baseline (eligibility ii visit) procedure * patient with a current diagnosis of nyha functional class ii/iii * patient with egfr levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150μmol/l exclusion criteria: * pregnant women or women planning a pregnancy within 12 months of study enrolment * patient with significant co-morbid condition(s) which, at the discretion of the pi, are deemed to prohibit study entry * patient with life expectancy of less than a year * concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor) * patient with pulmonary artery anatomy that precludes treatment * patient with moderate to severe pulmonary artery stenosis * patient with any pulmonary artery aneurysm * patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months * patient experiencing a current episode of acute decompensated heart failure * patient who has cardiac pacemakers/icd/crt-d that were implanted fewer than three months prior to enrolment. patient who has implantable cardiomems device, neurostimulators or drug infusion devices, regardless of implant date.
il6 on umbilical cord (evaluation of il-6 levels on umbilical cord)

Conditions: Intrauterine Infection; Fetus Disorder

Summary: fetal inflammatory response syndrome (firs) is a major cause of non-hypoxic fetal intrapartum injury. one of the most common determinants of firs during labor is the exposure to an ongoing intra-amniotic infectious agent as in the event of a chorioamnionitis. interleuchine-6 (il-6) is considered a reliable hallmark of firs. no specific fetal heart rate pattern for the diagnosis of firs have been described so far at intrapartum cardiotocography (ctg). the aim the present study is to investigate the correlation between intrapartum ctg findings and il-6 levels on the arterial cord.

the labor will be managed according to the local protocol and 5ml of blood will collected from the umbilical artery soon after birth to determine the il-6 values. cardiotocography (ctg) traces will be retrospectively reviewed by two expert operators that will be blinded to the il-6 results and will categorize them as "inflammatory" or "not inflammatory". inflammatory pattern will be defined in presence of 1) inappropriately high fhr for the given gestational age and/or 2) an increase \>10% compared with the fhr baseline values at admission without preceding deceleration with/without reduced variability or absent cycling. the association between ctg findings as the umbilical levels of il6 will be analyzed.

Eligibility criteria:
inclusion criteria: * singleton pregnancies at term submitted to a continuous ctg tracing during labor exclusion criteria:elective cesarean delivery, maternal tachycardia or pyrexia \>38°c, drugs assumption -
the effect of manual therapy on central sensitization

Conditions: Subacromial Pain Syndrome; Central Sensitisation

Summary: subacromial pain syndrome (sis) is a common cause of shoulder pain, estimated to be the cause for up to half of incident cases. typically, pain is generated with elevation of the arm above the head though it can occur with rest in patients with sis.there is evidence of central sensitization in those who experience chronic shoulder pain from sis. central sensitization is an augmentation of the nociceptive pathways of the central nervous system that is characterized by local and generalized lowered pain thresholds and an exaggerated pain response to painful and non painful stimulation.mobilization with movement (mwm) technic is a kind of manual therapy and it is often used by clinicians for the treatment of musculoskeletal diseases. usually manual therapy is used for its peripheral effects, however it also produces central analgesic effects activating descending anti-nociceptive pathways for a short period of time (30 - 35 mins.). some speculate that repeated sessions of manual therapy may result in a long term activation of descending anti-nociceptive pathways. however, there is no evidence of this mechanism available yet. therefore, the aim of this study is to investigate the effect of mwm on central sensitization (primary aim) and shoulder functions (secondary aim) in patients with sis.


Eligibility criteria:
inclusion criteria: * to have confirmed unilateral subacromial pain (positive testing at neer impingement and hawkins-kennedy tests), * to have \<40 score in central sensitization inventory. exclusion criteria: * to have bilateral subacromial pain, * to have any pathology (except subacromial pain) that give rise to central sensitization (this pathologies are summarized in central sensitization inventory - part b) * to have severe osteoarthritis or subluxation in shoulder joint, * to have adhesive capsulitis, * being treated with physiotherapy for this disorder at least one month before the start of the study. * to have severe cervical or lumbar radiculopathy,

Keywords: manual therapy shoulder pain mobilization
dry pleurodesis with talcum and afatinib is used to treat patients with non-small cell lung carcinoma

Conditions: Non Small Cell Lung Cancer

Summary: in non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is formed. currently, the most common and effective method of obliteration of the pleural cavity is pleurodesis with talcum powder. talc, when it surface of the pleura, causes chemical inflammation that leads to the soldering of the lungs and chest wall. as a result, the liquid ceases to accumulate. the addition of a therapeutic dose of afatinib to talc not only blocks effusion into the pleural cavity, but also reduces tumor and metastatic processes.

the proposed procedure for dry pleurodesis consists of one stage. talc is introduced into the pleural cavity in several ways: * drainage - a tube is inserted into the pleural cavity through a puncture in the chest, and then a pasty talcum is delivered into the cavity, which spreads through the cavity during the change of the patient's body position. * talcum powder - under the control of thoracoscopy, dry talc is blown into the pleural cavity of the patient, which allows him to evenly distribute and significantly increases the effectiveness of the procedure. in this clinical trial investigators will use the method of thoracoscopy - the blow in of talcum powder and therapeutic dose of afatinib. before injection, a suspension of talc and afatinib is subjected to the procedure of pharmaceutical mixing. the operation is well tolerated by participants and lasts no more than 30 minutes. the effectiveness of the method is 90%.

Eligibility criteria:
inclusion criteria: * non-small cell lung cancer with positive mutation of egfr verified * malignant pleural effusion * recurrent pleural effusion * complete lung expansion (\> 80%) after puncture emptying confirmed by chest radiography. * karnofsky index \> 50 * agreed to participate in the study and sign an informed consent exclusion criteria: * radiotherapy not earlier than 3 months before the pleurodesis procedure * previous surgeries on the same hemitorace * thrombocytopenia or coagulation disorders * trapped lung syndrome * patients with estimated life expectancy \< 4-8 weeks * pleural or active systemic infection

Keywords: afatinib talcum powder thoracoscopy pleurodesis bibw2992
influence of inguinal hernia repair on sperm autoimmunity

Conditions: Male Infertility Due to Antisperm Antibody

Summary: influence of inguinal hernia repair on sperm autoimmunity using mar test

all infertile male patients, visited between february 2000 and september 2020 and which were tested with mar (mixed autoglobulin reaction) test, were included in this retrospective study. sperm quality (number of spermatozoa, motility, vitality and normal forms) were also studied in this patients. the aim of the study is to evaluate if there is a higher incidence of positive mar test among patients undergoing inguinal hernioplasty compared to the general population

Eligibility criteria:
inclusion criteria: * patients undergone to correction of inguinal hernia exclusion criteria: * no specific exclusion criteria were set.
virtual reality-based eye movement desensitisation and reprocessing therapy for specific phobias

Conditions: Specific Phobias

Summary: the goal of this clinical trial is to study the effectiveness of a virtual reality-based eye movement desensitization and reprocessing (emdr) application in treating phobia. it will also learn about the feasibility and safety of the application for independent use. the main questions it aims to answer are: does the vr emdr application reduce distress, improve positive cognitions, and decrease avoidance of specific phobias? can the application help diminish phobia-related bodily sensations and encourage cognitive shifts toward positive beliefs and greater confidence in confronting previously avoided situations? can the participants independently administer the treatment with minimum assistance? participants will: visit the site and take the vr emdr phobia treatment every day for one week. report their phobia and simulator sickness symptoms through self-report questionnaires or semi-structured interviews.


Eligibility criteria:
inclusion criteria: * have a specific phobia (not necessarily clinically significant) exclusion criteria: * diagnosis of mental health disorders * history of trauma associated with their phobia * history of panic attacks associated with their phobia * history of psychosis * current self-harm * current suicidal ideation * regular use of substances that might affect mental state * regular use of medications that might affect mental state * significant visual impairments * severe motion sickness

Keywords: eye movement desensitization and reprocessing (emdr) virtual reality
evaluation of the effects using the combination of sedative agents on dental anxiety in pediatric patients

Conditions: Anxiety Postoperative

Summary: the aims of this study were firstly, to evaluate the changes in the anxiety level after deep sedation with various intravenous sedative agents using salivary cortisol level in pediatric dental patients and secondly, to compare clinical effectiveness of this sedative agents, perioperative complications, recovery time and adverse effects.

this clinical study was included 69 healthy pediatric patients aged 3 to 7 years with high anxiety. the patients were divided into 3 groups according to the sedative agents: group 1 (n=23) was received propofol, group 2 (n=23) was receieved ketofol 1:3, and group 3 (n=23) was received ketofol 1:4. the anxiety levels were assessed using facial image scale (fis) anxiety scale and changes in salivary cortisol levels were assessed using elisa before and after the drug administration. perioperative vital signs, depth of sedation were recorded at intervals of 5 minutes. preoperative and postoperative complications, operation and recovery time were recorded in the follow-up form.

Eligibility criteria:
inclusion criteria: * pediatric patients age between 3-7 years old * having no systemic condition and asa 1 healty status * having high dental anxiety * having no dental treatment under the sedation or general anesthesia before * having no dental treatment before exclusion criteria: * having obstructed nasal passages, raised intracranial or intraocular pressure, allergy * using any drug which effected saliva construction * having enough saliva for saliva cortisol evaluation

Keywords: dental anxiety deep sedation ketofol propofol salivary cortisol